Stockreport

Tempus Announces Strategic Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Clinical Differentiation Across an ADC Clinical Program

DAIICHI SANKYO S/ADR  (DSNKY) 
PDF CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc., a leader in artificial intelligence and precision medicine, today announced a strategic collaboration with Daiichi Sankyo [Read more]